The National Institutes of Health is sunsetting its influential COVID-19 treatment guidelines, used by millions of doctors to guide care during the pandemic.

Insurers, employers, taxpayers and other consumers will all be affected as drugmakers move these products to the commercial market in May. How much you'll pay depends on your health insurance.

The drug is the most effective way to cut the risk of severe disease. It's heading to China now. Yet the drug is underused in some places. Why? And are there options if you're not a good candidate?

The treatments were highly popular earlier in the pandemic. One by one, they got knocked out by more convenient, less expensive treatment options, and new COVID variants.

Some people have had trouble getting Paxlovid pills quickly, despite the administration's effort to ease access after a COVID test confirms infection.

States and health providers report they've dispensed less than half their supply from the government, raising fears that the drugs may go to waste while people who could benefit get sicker.

NPR has obtained the government's $5.3 billion contract for the first 10 million courses of Paxlovid, an antiviral pill for COVID-19. Here's what's in it.

So far the government has distributed about 300,000 doses of Evusheld, a new drug that protects against COVID-19. Some 7 million Americans could benefit from the drug right away.

Paxlovid and molnupiravir have been authorized for emergency use to keep COVID-19 patients out of the hospital, but don't expect to be able to go to your usual pharmacy and get them.

In a highly anticipated decision, the Food and Drug Administration authorized Pfizer's Paxlovid as the first antiviral pill to treat COVID-19 at home.

The FDA is considering new pills that could treat people in early stages of COVID. Here's what to know about how they work, how effective they are and the impact they could make on the pandemic.

Dalton’s new Regeneron treatment drive-in clinic helped about 60 people receive Regeneron’s monoclonal antibody treatment for early diagnosed COVID-19 cases. The city council believes this clinic is the first of its kind in Georgia.

Jennifer Minhas is among those who suffer lingering problems after COVID-19. A diagnosis of POTS, a little-known circulation disorder that mostly affects women, offers a way forward.

Researchers are reporting some progress in their search for drugs that tamp down the overwhelming immune reaction that can kill a patient with COVID-19.

While logistical challenges have hampered use of antibody drugs to treat people with mild-to-moderate COVID-19, recent results show the medicines can be worthwhile.